Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials
After accounting for therapeutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared with interferon β-1a, reduces disability progression during secondary progressive multiple sclerosis.
Authors
- Tomáš Kalinčík (ORCID: https://orcid.org/0000-0003-3778-1376)
- Izanne Roos (ORCID: https://orcid.org/0000-0003-0371-3666)
- Winston Dzau (ORCID: https://orcid.org/0000-0001-8591-6605)
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
Publication Details
- Journal
- Journal of Neurology Neurosurgery & Psychiatry
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1136/jnnp-2024-335495
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00